Bobo Donald E Jr reported option exercise involving 48,900 derivative units of Edwards Lifesciences Corp at $0.00 for $0 on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CVP,Strategy/Corp Development
CVP,Strategy/Corp Development
Filed Nov 9, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
48,900Employee Stock Option (Right to Acquire)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 9, 2026, 4:29 PM ET0-day reporting delay
Accession
0001225208-26-008779Code M · Transaction 395952
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Sell48,900$103.05−$5,039,311.26Trade 395951
Nov 9, 2026Option exercise48,900$72.68$3,554,052Trade 395950
3 transaction rows in this filing. Joint filers share the same rows.

EW price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
EW · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −17%1w ago −8.7%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2026. F2: This transaction was executed in multiple trades at prices ranging from $103.00 to $103.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.